An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pK.sub.a that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pK.sub.a that is within 1 unit of the pH of step (a).

The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.

A plant-based food product with zero sugar is provided. The plant-based food product includes an amount of water, a sugar content of between 0 wt % and 0.4 wt % referred to as having zero sugar, and a plant-based fiber product. The plant-based fiber product includes an amount of water, a plant-based flour, an amount of plant fiber, and a plurality of enzymes comprising: an alpha amylase, a glucose oxidase, catalase, and a cellulase. The plant-based food product may be incorporated in a milk, yogurt, shake, or bar, for example.

The present invention provides compositions and methods for producing magnetic bionanocatalysts (BNCs) comprising metabolically self-sufficient systems of enzymes that include P450 monooxygenases or other metabolic enzymes and cofactor regeneration enzymes.

The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.

Compositions and methods for the treatment of skin disorders or disease are provided.

Agents, kits, and methods that utilize oxygenation to prevent and/or treat infections caused by anaerobic microorganisms are provided. The agents, kits, and methods according to several embodiments utilize oxygenation in the intestinal lumen to prevent and/or treat infections caused by anaerobic bacteria. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.

Embodiments of the present disclosure relate to a D-amino acid oxidase mutant and application in preparing L-glufosinate thereof. The D-amino acid oxidase mutant has an amino acid substitution at at least one of position 62 and position 226 of an amino acid sequence of the D-amino acid oxidase mutant when compared to an amino acid sequence of a D-amino acid oxidase as set forth in SEQ ID NO. 1, the position 62 and position 226 being defined with reference to SEQ ID NO. 1, and the amino acid sequence of the D-amino acid oxidase mutant having at least 90% identity to SEQ ID NO. 1.

The present invention generally relates to the field of fermentation technology and microorganisms useful for such fermentations. The invention also relates to materials including nucleic acids and proteins useful for altering fermentation characteristics of microorganisms, and to microorganisms comprising such nucleic acids and/or proteins.

The present application relates to sustained release formulations of crystalline drugs, comprising a crystalline drug core and a polymer shell, wherein the polymer comprises PLA and/or PLGA and the shell completely encapsulates the core. The sustained release formulations are suitable for drugs such as steroid or proteins. The present invention also relates to methods of the manufacture of the sustained release formulations, using either pressing alone or pressing in combination with heating.